278 related articles for article (PubMed ID: 37361539)
1. HIF and MYC signaling in adrenal neoplasms of the neural crest: implications for pediatrics.
Bechmann N; Westermann F; Eisenhofer G
Front Endocrinol (Lausanne); 2023; 14():1022192. PubMed ID: 37361539
[TBL] [Abstract][Full Text] [Related]
2. Neural crest development and neuroblastoma: the genetic and biological link.
Nakagawara A
Prog Brain Res; 2004; 146():233-42. PubMed ID: 14699967
[TBL] [Abstract][Full Text] [Related]
3. CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours.
Vega FM; Colmenero-Repiso A; Gómez-Muñoz MA; Rodríguez-Prieto I; Aguilar-Morante D; Ramírez G; Márquez C; Cabello R; Pardal R
EBioMedicine; 2019 Nov; 49():82-95. PubMed ID: 31685444
[TBL] [Abstract][Full Text] [Related]
4. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche.
Pietras A; Gisselsson D; Ora I; Noguera R; Beckman S; Navarro S; Påhlman S
J Pathol; 2008 Mar; 214(4):482-8. PubMed ID: 18189331
[TBL] [Abstract][Full Text] [Related]
5. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
[TBL] [Abstract][Full Text] [Related]
6. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
7. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
[TBL] [Abstract][Full Text] [Related]
8. Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis.
Mobley BC; Kwon M; Kraemer BR; Hickman FE; Qiao J; Chung DH; Carter BD
PLoS One; 2015; 10(7):e0133897. PubMed ID: 26222553
[TBL] [Abstract][Full Text] [Related]
9. Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells.
Mukae K; Takenobu H; Endo Y; Haruta M; Shi T; Satoh S; Ohira M; Funato M; Toguchida J; Osafune K; Nakahata T; Kanda H; Kamijo T
Cancer Sci; 2023 May; 114(5):1898-1911. PubMed ID: 36661413
[TBL] [Abstract][Full Text] [Related]
10. CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.
Zage PE; Whittle SB; Shohet JM
J Cell Biochem; 2017 Feb; 118(2):221-231. PubMed ID: 27428599
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.
Kerosuo L; Neppala P; Hsin J; Mohlin S; Vieceli FM; Török Z; Laine A; Westermarck J; Bronner ME
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7351-E7360. PubMed ID: 30021854
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
13. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
14. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
15. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
16. Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.
Wulf AM; Moreno MM; Paka C; Rampasekova A; Liu KJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769149
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.
Qing G; Skuli N; Mayes PA; Pawel B; Martinez D; Maris JM; Simon MC
Cancer Res; 2010 Dec; 70(24):10351-61. PubMed ID: 20961996
[TBL] [Abstract][Full Text] [Related]
18. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
19. HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells.
Pietras A; Hansford LM; Johnsson AS; Bridges E; Sjölund J; Gisselsson D; Rehn M; Beckman S; Noguera R; Navarro S; Cammenga J; Fredlund E; Kaplan DR; Påhlman S
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16805-10. PubMed ID: 19805377
[TBL] [Abstract][Full Text] [Related]
20. Composite pheochromocytoma: a clinicopathologic and molecular comparison with ordinary pheochromocytoma and neuroblastoma.
Comstock JM; Willmore-Payne C; Holden JA; Coffin CM
Am J Clin Pathol; 2009 Jul; 132(1):69-73. PubMed ID: 19864235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
